Medtronic, Inc. (MDT) Submitted Pre-Market Approval Application For FDA Approval of InterStim(R) Therapy for Fecal Incontinence
10/22/2008 11:06:49 AM
MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that it has submitted its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for InterStim® Therapy for the treatment of fecal incontinence. InterStim Therapy is a reversible treatment for patients with fecal incontinence after conservative treatments have failed. Once approved by the FDA, InterStim Therapy for fecal incontinence will be the only therapy that allows patients and physicians to trial the therapy with a minimally invasive test stimulation to confirm its effect prior to the device implant.
comments powered by